Sengwee Toh, ScD; Christian Hampp, PhD; Marsha E. Reichman, PhD; David J. Graham, MD, MPH; Suchitra Balakrishnan, MD, PhD; Frank Pucino, PharmD, MPH; Jack Hamilton, AB; Samuel Lendle, PhD; Aarthi Iyer, JD, MPH; Malcolm Rucker, MS; Madelyn Pimentel, BA; Neesha Nathwani, BS; Marie R. Griffin, MD, MPH; Nancy J. Brown, MD; Bruce H. Fireman, MA
Several postmarketing placebo-controlled trials and observational studies have provided conflicting results on the risk for hospitalized heart failure (hHF) among patients using dipeptidyl peptidase-4 (DPP-4) inhibitors. This analysis of a large cohort of patients seen in ambulatory care compared the risk for hHF among new users of 2 DPP-4 inhibitors (saxagliptin or sitagliptin) versus new users of second-generation sulfonylureas, pioglitazone, or long-acting insulin products.
Ann Intern Med. 2016;164(11):705-714. doi:10.7326/M15-2568
Michael W. Yeh, MD; Hui Zhou, PhD; Annette L. Adams, PhD; Philip H.G. Ituarte, PhD, MPH; Ning Li, PhD; In-Lu Amy Liu, MS; Philip I. Haigh, MD
The comparative effectiveness of surgical and medical treatments on fracture risk in primary hyperparathyroidism (PHPT) is unknown. In this retrospective cohort study, the authors sought to determine the effects of parathyroidectomy, bisphosphonates, and observation on skeletal outcomes in patients with PHPT.
Ann Intern Med. 2016;164(11):715-723. doi:10.7326/M15-1232
Adrian Reuben, MBBS; Holly Tillman, MS; Robert J. Fontana, MD; Timothy Davern, MD; Brendan McGuire, MD; R. Todd Stravitz, MD; Valerie Durkalski, PhD; Anne M. Larson, MD; Iris Liou, MD; Oren Fix, MD; Michael Schilsky, MD; Timothy McCashland, MD; J. Eileen Hay, MBBS; Natalie Murray, MD; Obaid S. Shaikh, MD; Daniel Ganger, MD; Atif Zaman, MD; Steven B. Han, MD; Raymond T. Chung, MD; Alastair Smith, MB, ChB; Robert Brown, MD; Jeffrey Crippin, MD; M. Edwyn Harrison, MD; David Koch, MD; Santiago Munoz, MD; K. Rajender Reddy, MD; Lorenzo Rossaro, MD; Raj Satyanarayana, MD; Tarek Hassanein, MD; A. James Hanje, MD; Jody Olson, MD; Ram Subramanian, MD; Constantine Karvellas, MD; Bilal Hameed, MD; Averell H. Sherker, MD; Patricia Robuck, PhD; William M. Lee, MD
Whether changes have occurred in the causes of acute liver failure (ALF), its management, or the survival of patients with the condition with or without liver transplantation is not known. This large cohort of patients with ALF referred to specialized centers evaluated changes in causes, treatment, and survival over 16 years.
Ann Intern Med. 2016;164(11):724-732. doi:10.7326/M15-2211
Quinn Grundy, PhD, RN; Lisa A. Bero, PhD; Ruth E. Malone, PhD, RN
Concerns about conflicts of interest among health care workers have focused on interactions between industry representatives and prescribing clinicians. In this qualitative, ethnographic study, the authors sought to describe industry activities targeted at registered nurses and addressed common assumptions about nurses' interactions with industry.
Ann Intern Med. 2016;164(11):733-739. doi:10.7326/M15-2522
Nisa M. Maruthur, MD, MHS; Eva Tseng, MD, MPH; Susan Hutfless, PhD; Lisa M. Wilson, ScM; Catalina Suarez-Cuervo, MD; Zackary Berger, MD, PhD; Yue Chu, MSPH; Emmanuel Iyoha, MBChB, MPH; Jodi B. Segal, MD, MPH; Shari Bolen, MD, MPH
In this review, the authors delineate the comparative effectiveness and safety of metformin and metformin-based combinations, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, sodium–glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists for adults with type 2 diabetes.
Ann Intern Med. 2016;164(11):740-751. doi:10.7326/M15-2650
Xin-Lin Zhang, MD; Li Zhu, MD; Zhong-Hai Wei, MD; Qing-Qing Zhu, MD; Jian-Zhong Qiao, MM; Qing Dai, MM; Wei Huang, MD; Xiao-Hong Li, MD; Jun Xie, MD; Li-Na Kang, MD; Lian Wang, MD; Biao Xu, MD, PhD
Preliminary evidence from 6 randomized, controlled trials and 38 observational studies suggests that the new everolimus-eluting bioresorbable vascular scaffold used in percutaneous coronary intervention may have important harms.
Ann Intern Med. 2016;164(11):752-763. doi:10.7326/M16-0006
Risa B. Burns, MD, MPH; Carol K. Bates, MD; Pamela Hartzband, MD; Gerald W. Smetana, MD
This Grand Rounds summarizes a discussion between 2 experts about treating subclinical hypothyroidism and how they would balance the benefits and harms of treatment both in general and in a specific patient.
Ann Intern Med. 2016;164(11):764-770. doi:10.7326/M16-0857
Joseph V. Selby, MD, MPH
Toh and colleagues report an evaluation of the risks of DPP-4 inhibitors using health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program. The editorial discusses how sharing complementary data resources could achieve many goals, including answering safety and effectiveness questions quickly and more definitively and linking clinical trial investigation with real-world experience.
Ann Intern Med. 2016;164(11):771-772. doi:10.7326/M16-0869
Connie M. Ulrich, PhD, RN; Christine Grady, PhD, RN
Grundy and colleagues give us an opening glance at the personal narratives of nurse–industry relationships from nonprescribing practicing nurses. The editorialists discuss that, because registered nurses are integral members of health care teams in hospitals and other health care settings, they interact with many other individuals and are not immune to potential conflicts of interest.
Ann Intern Med. 2016;164(11):773-774. doi:10.7326/M16-0707
Seth S. Martin, MD, MHS; Rani K. Hasan, MD, MHS
Zhang and colleagues report a meta-analysis that evaluates the effectiveness and safety of implantation of an everolimus-eluting bioresorbable vascular scaffold (BVS) versus a current-generation, nonresorbable everolimus-eluting metallic stent in patients having percutaneous coronary intervention. The editorial notes that BVS is still in the early stages, and long-term postmarketing surveillance will be needed to ensure both safety and efficacy in broader populations.
Ann Intern Med. 2016;164(11):775-776. doi:10.7326/M16-0754
Veneta Masson, RN, MA
Ann Intern Med. 2016;164(11):763. doi:10.7326/M16-0241
Ann B. Nattinger, MD, MPH; Julie L. Mitchell, MD, MS
Ann Intern Med. 2016;164(11):ITC81-ITC96. doi:10.7326/AITC201606070
Darren B. Taichman, MD, PhD
Ann Intern Med. 2016;164(11):ED11. doi:10.7326/AFED201606070
William J. Doan, BA, MFA, PhD
Annals Graphic Medicine brings together original graphic narratives, comics, animation/video, and other creative forms by those who provide or receive health care. They address medically relevant topics—whether they be poignant, thought-provoking, or just plain entertaining. Find more at www.annals.org/GraphicMedicine.
Ann Intern Med. 2016;164(11):W15-W24. doi:10.7326/G15-0018
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use